FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

L										
	OMB Number:	3235-0287								
	Estimated average burden									
	hours per response:	0.5								

STATEMENT OF CHANGES IN BENEFICIAL OWNERS

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	ess of Reporting Pers	son [*]	2. Issuer Name and Ticker or Trading Symbol Orchestra BioMed Holdings, Inc. [OBIO]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Sherman Darren			Orenestra biolited Holdings, me. [Obio]	X	Director	10% Owner					
(Last) C/O ORCHEST	(First) FRA BIOMED H	(Middle) OLDINGS, INC.	3. Date of Earliest Transaction (Month/Day/Year) 01/26/2023	X	Officer (give title below) See Reman	Other (specify below) rks					
150 UNION SC	QUARE DRIVE		4. If Amendment, Date of Original Filed (Month/Day/Year) 01/30/2023	6. Individual or Joint/Group Filing (Check Applica Line)							
(Street)				X	Form filed by One Reporting Person						
NEW HOPE	РА	18938		Form filed by More than One Reporting Person							
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication								
			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		4. Securities A Disposed Of (E				6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	 Reported Transaction(s) (Instr. 3 and 4) 		(Instr. 4)
Common Stock, par value \$0.0001 per share ("Common Stock")	01/26/2023		A		68,819(1)(2)	A	(3)	68,819(1)	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Right to Receive Earnout Shares ⁽¹⁾	(4)	01/26/2023		A		29,918		(4)	(4)	Common Stock	29,918	(4)	29,918	D		

Explanation of Responses:

1. On January 30, 2023, the Reporting Person filed a Form 4 which inadvertently (1) misstated the number of shares of Common Stock acquired by the Reporting Person in the Business Combination (defined below) as 68,189 instead of the correct 68,819 shares of Common Stock and (2) omitted the right to receive Earnout Shares (defined below). In accordance with Instructions 9(a) and 9(b) to Form 4, this amendment is filed solely to (1) correct the amounts in Table I, Column 5 and (2) add the lines of information to Table II included here; as provided in that instruction, the remainder of the information in the original filing is not restated in this amendment, and no other amendment is made to the original filing.

2. These securities were issued on the closing date of the merger (the "Business Combination") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 (as amended, the "Merger Agreement"), by and among Orchestra BioMed Holdings, Inc. (*f/k/a* Health Sciences Acquisitions Corporation 2) ("HSAC2"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation ("Legacy Orchestra"), in exchange for Legacy Orchestra securities.

3. Received in the Business Combination in exchange for 147,998 shares of common stock of Legacy Orchestra ("Legacy Orchestra Common Stock").

4. Pursuant to the Merger Agreement, the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, \$15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, \$20.00 per share over any 20 trading days within any 30-trading day period.

Remarks:

President and Chief Operating Officer

/s/ Matthew R. Schob,

Attorney-in-Fact

05/05/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.